That’s about 15%-18% of total population and a substrata of proneural does seem to respond. There may also be a way to induce mesenchymal transition in some but further assessment of risk and benefit must be made. Best wishes.
Hankmanhub, only about 15% of the GBM population had the Proneural antigenic type and DCVax-L is Per Dr. Liau not very effective for that type of cancer.
Consequently, not much revenue will be lost by removing this small group from the GBM category especially when the DCVax-L treatment does not work well in such patients.
Furthermore, I am betting that in the future a lot of revenue will be earned from the treatment of a variety of solid inoperable cancers with DCVax- Direct and from DCVax-L designed to treat a variety of operable cancers.
News 
Market Data 
Discover 
AI
